Literature DB >> 22751111

The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas.

E Pérez-Gómez1, C Andradas, J M Flores, M Quintanilla, J M Paramio, M Guzmán, C Sánchez.   

Abstract

G protein-coupled receptors (GPCRs) control crucial physiological processes and their dysfunction contributes to various human diseases, including cancer. The orphan GPCR GPR55 was identified and cloned more than a decade ago, but very little is known about its physio-pathological relevance. It has been recently shown that GPR55 controls the behavior of human cancer cell lines in culture and xenografts. However, the assessment of the actual role of this receptor in malignant transformation in vivo is hampered by the lack of studies on its functional impact in clinically-relevant models of cancer. Here we demonstrate that GPR55 drives mouse skin tumor development. Thus, GPR55-deficient mice were more resistant to DMBA/TPA-induced papilloma and carcinoma formation than their wild-type littermates. GPR55 exerted this pro-tumor effect primarily by conferring a proliferative advantage on cancer cells. In addition, GPR55 enhanced skin cancer cell anchorage-independent growth, invasiveness and tumorigenicity in vivo, suggesting that it promotes not only tumor development but also tumor aggressiveness. Finally, we observed that GPR55 is upregulated in human skin tumors and other human squamous cell carcinomas compared with the corresponding healthy tissues. Altogether, these findings reveal the pivotal importance of GPR55 in skin tumor development, and suggest that this receptor may be used as a new biomarker and therapeutic target in squamous cell carcinomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22751111     DOI: 10.1038/onc.2012.278

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  36 in total

1.  Design, synthesis, and analysis of antagonists of GPR55: Piperidine-substituted 1,3,4-oxadiazol-2-ones.

Authors:  Maria Elena Meza-Aviña; Mary A Lingerfelt; Linda M Console-Bram; Thomas F Gamage; Haleli Sharir; Kristen E Gettys; Dow P Hurst; Evangelia Kotsikorou; Derek M Shore; Marc G Caron; Narasinga Rao; Larry S Barak; Mary E Abood; Patricia H Reggio; Mitchell P Croatt
Journal:  Bioorg Med Chem Lett       Date:  2016-02-16       Impact factor: 2.823

2.  The LPI/GPR55 axis enhances human breast cancer cell migration via HBXIP and p-MLC signaling.

Authors:  Xiao-Lei Zhou; Xin Guo; Yu-Pin Song; Chong-Yue Zhu; Wei Zou
Journal:  Acta Pharmacol Sin       Date:  2017-11-30       Impact factor: 6.150

3.  Concurrent activation of β2-adrenergic receptor and blockage of GPR55 disrupts pro-oncogenic signaling in glioma cells.

Authors:  Artur Wnorowski; Justyna Such; Rajib K Paul; Robert P Wersto; Fred E Indig; Krzysztof Jozwiak; Michel Bernier; Irving W Wainer
Journal:  Cell Signal       Date:  2017-05-08       Impact factor: 4.315

Review 4.  Minireview: ubiquitination-regulated G protein-coupled receptor signaling and trafficking.

Authors:  Verónica Alonso; Peter A Friedman
Journal:  Mol Endocrinol       Date:  2013-03-07

5.  Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling.

Authors:  N A Balenga; E Martínez-Pinilla; J Kargl; R Schröder; M Peinhaupt; W Platzer; Z Bálint; M Zamarbide; I G Dopeso-Reyes; A Ricobaraza; J M Pérez-Ortiz; E Kostenis; M Waldhoer; A Heinemann; R Franco
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 6.  Hunting for the function of orphan GPCRs - beyond the search for the endogenous ligand.

Authors:  Raise Ahmad; Stefanie Wojciech; Ralf Jockers
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

7.  GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine.

Authors:  R Ferro; A Adamska; R Lattanzio; I Mavrommati; C E Edling; S A Arifin; C A Fyffe; G Sala; L Sacchetto; G Chiorino; V De Laurenzi; M Piantelli; O J Sansom; T Maffucci; M Falasca
Journal:  Oncogene       Date:  2018-07-30       Impact factor: 9.867

8.  (R,R')-4'-methoxy-1-naphthylfenoterol targets GPR55-mediated ligand internalization and impairs cancer cell motility.

Authors:  Rajib K Paul; Artur Wnorowski; Isabel Gonzalez-Mariscal; Surendra K Nayak; Karolina Pajak; Ruin Moaddel; Fred E Indig; Michel Bernier; Irving W Wainer
Journal:  Biochem Pharmacol       Date:  2013-12-16       Impact factor: 5.858

Review 9.  Insights into the effects of the endocannabinoid system in cancer: a review.

Authors:  Ana Isabel Fraguas-Sánchez; Cristina Martín-Sabroso; Ana Isabel Torres-Suárez
Journal:  Br J Pharmacol       Date:  2018-05-22       Impact factor: 8.739

10.  Emerging Roles of Cannabinoids and Synthetic Cannabinoids in Clinical Experimental Models.

Authors:  Paula Morales; Patricia H Reggio
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.